title: Prevalence of breakthrough in chronic hepatitis C patients undergoing antiviral therapy: role of type and schedule of alpha interferon C.H.S.G.
authors.forename: G
authors.initials: G
authors.lastname: Bellati
authors.forename: G
authors.initials: G
authors.lastname: Colloredo
authors.forename: L
authors.initials: L
authors.lastname: Roffi
authors.forename: M
authors.initials: M
authors.lastname: D'Aquino
authors.forename: F
authors.initials: F
authors.lastname: Bonino
authors.forename: G
authors.initials: G
authors.lastname: Idéo
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D004334:Drug Administration Schedule; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins